VANCOUVER, BRITISH COLUMBIA--(Marketwire - August 11, 2009) - enGene Inc., a privately held biotechnology company with a proprietary, polymer-based nucleotide delivery technology called GEMS™ (Gut Epithelial cell Modification System), announced today that Eric A. Adams, CEO, will present at the Rodman and Renshaw 11th Annual Healthcare Conference on September 11, 2009, 10:05 am (EST) at the New York Palace Hotel in New York City.
Mr. Adams will be presenting an update on the Company's plans to advance its two lead programs - GEMS-Insulin for Type 1 diabetes and GEMS-IL10 for inflammatory bowel disease (IBD). enGene recently completed a large animal study for GEMS-Insulin that demonstrated a potentially very significant breakthrough: the ability to re-establish a functioning, self-regulating in vivo insulin control system by producing and releasing insulin from the duodenum, in the proper quantity and at the appropriate time, to regulate blood glucose levels. In the GEMS-IL10 program the Company has achieved several significant milestones in showing feasibility and efficacy in animal models of IBD: demonstrating a reduction in gut inflammation, improvement in weight and expedited tissue healing in treated animals. Based on these successes and other progress in product development, Mr. Adams will be presenting the Company's plans to complete remaining animal testing and enter into human clinical trials.
More about enGene Inc. and GEMS™
enGene's GEMS technology utilizes the natural capacity of existing, normal, healthy cells in the gastrointestinal tract to produce therapeutic protein drugs by delivering nucleotides in a novel, polymer-based vector. In addition to diabetes and IBD, other applications under development for GEMS include siRNA delivery, vaccines, and delivery of therapeutic proteins to treat Type 2 diabetes and hemophilia.
Additional information about the Company is available at www.engeneinc.com.